AR016243A1 - Un anticuerpo proteico que tiene las regiones determinantes de la complementariedad del anticuerpo monoclonal f19 y que se fija especificamente a laproteina de activacion de fibroblastos; el empleo de dicho anticuerpo proteico para el tratamiento del cancer, para representar en imagenes fibroblastos - Google Patents
Un anticuerpo proteico que tiene las regiones determinantes de la complementariedad del anticuerpo monoclonal f19 y que se fija especificamente a laproteina de activacion de fibroblastos; el empleo de dicho anticuerpo proteico para el tratamiento del cancer, para representar en imagenes fibroblastosInfo
- Publication number
- AR016243A1 AR016243A1 ARP990102015A ARP990102015A AR016243A1 AR 016243 A1 AR016243 A1 AR 016243A1 AR P990102015 A ARP990102015 A AR P990102015A AR P990102015 A ARP990102015 A AR P990102015A AR 016243 A1 AR016243 A1 AR 016243A1
- Authority
- AR
- Argentina
- Prior art keywords
- antibody
- protein
- protein antibody
- tumor
- fibroblast
- Prior art date
Links
- 102000004169 proteins and genes Human genes 0.000 title abstract 13
- 108090000623 proteins and genes Proteins 0.000 title abstract 13
- 210000002950 fibroblast Anatomy 0.000 title abstract 9
- 206010028980 Neoplasm Diseases 0.000 title abstract 8
- 230000004913 activation Effects 0.000 title abstract 2
- 201000011510 cancer Diseases 0.000 title abstract 2
- 210000004027 cell Anatomy 0.000 abstract 4
- 238000000034 method Methods 0.000 abstract 4
- 206010061218 Inflammation Diseases 0.000 abstract 2
- 230000004054 inflammatory process Effects 0.000 abstract 2
- 239000002773 nucleotide Substances 0.000 abstract 2
- 125000003729 nucleotide group Chemical group 0.000 abstract 2
- 108020004414 DNA Proteins 0.000 abstract 1
- 108020004511 Recombinant DNA Proteins 0.000 abstract 1
- 206010052428 Wound Diseases 0.000 abstract 1
- 208000027418 Wounds and injury Diseases 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 238000012258 culturing Methods 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 230000035876 healing Effects 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000012986 modification Methods 0.000 abstract 1
- 230000004048 modification Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000029663 wound healing Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP98107925A EP0953639A1 (en) | 1998-04-30 | 1998-04-30 | FAPalpha-specific antibody with improved producibility |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR016243A1 true AR016243A1 (es) | 2001-06-20 |
Family
ID=8231860
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP990102015A AR016243A1 (es) | 1998-04-30 | 1999-04-30 | Un anticuerpo proteico que tiene las regiones determinantes de la complementariedad del anticuerpo monoclonal f19 y que se fija especificamente a laproteina de activacion de fibroblastos; el empleo de dicho anticuerpo proteico para el tratamiento del cancer, para representar en imagenes fibroblastos |
Country Status (27)
| Country | Link |
|---|---|
| EP (2) | EP0953639A1 (enExample) |
| JP (1) | JP4421779B2 (enExample) |
| KR (1) | KR100580936B1 (enExample) |
| CN (1) | CN1303430A (enExample) |
| AR (1) | AR016243A1 (enExample) |
| AT (1) | ATE356873T1 (enExample) |
| AU (1) | AU760305B2 (enExample) |
| BG (1) | BG65034B1 (enExample) |
| BR (1) | BR9910577A (enExample) |
| CA (1) | CA2327586C (enExample) |
| CO (1) | CO5050255A1 (enExample) |
| DE (1) | DE69935516T2 (enExample) |
| EA (1) | EA005401B1 (enExample) |
| EE (1) | EE200000642A (enExample) |
| ES (1) | ES2283114T3 (enExample) |
| HU (1) | HUP0101501A3 (enExample) |
| ID (1) | ID26555A (enExample) |
| IL (1) | IL138701A0 (enExample) |
| NO (1) | NO20005412L (enExample) |
| NZ (1) | NZ508456A (enExample) |
| PL (1) | PL358087A1 (enExample) |
| SK (1) | SK16192000A3 (enExample) |
| TR (1) | TR200003181T2 (enExample) |
| UA (1) | UA73276C2 (enExample) |
| WO (1) | WO1999057151A2 (enExample) |
| YU (1) | YU66300A (enExample) |
| ZA (1) | ZA200005506B (enExample) |
Families Citing this family (82)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7883704B2 (en) | 1999-03-25 | 2011-02-08 | Abbott Gmbh & Co. Kg | Methods for inhibiting the activity of the P40 subunit of human IL-12 |
| US6914128B1 (en) | 1999-03-25 | 2005-07-05 | Abbott Gmbh & Co. Kg | Human antibodies that bind human IL-12 and methods for producing |
| CA2401252A1 (en) * | 2000-03-17 | 2001-09-20 | Boehringer Ingelheim Pharma Kg | Human and humanized fap-alpha-specific antibodies |
| PE20021080A1 (es) * | 2001-04-12 | 2003-02-12 | Boehringer Ingelheim Int | Un anticuerpo especifico fapo bibh1 en el tratamiento del cancer |
| WO2004001004A2 (en) * | 2002-06-21 | 2003-12-31 | Johns Hopkins University School Of Medicine | Membrane associated tumor endothelium markers |
| US8968730B2 (en) | 2002-08-14 | 2015-03-03 | Macrogenics Inc. | FcγRIIB specific antibodies and methods of use thereof |
| US8044180B2 (en) | 2002-08-14 | 2011-10-25 | Macrogenics, Inc. | FcγRIIB specific antibodies and methods of use thereof |
| JP4459810B2 (ja) * | 2002-08-14 | 2010-04-28 | マクロジェニクス，インコーポレーテッド | ＦｃγＲＩＩＢ特異的抗体とその利用法 |
| US8530627B2 (en) | 2002-08-14 | 2013-09-10 | Macrogenics, Inc. | FcγRIIB specific antibodies and methods of use thereof |
| US8193318B2 (en) | 2002-08-14 | 2012-06-05 | Macrogenics, Inc. | FcγRIIB specific antibodies and methods of use thereof |
| US8946387B2 (en) | 2002-08-14 | 2015-02-03 | Macrogenics, Inc. | FcγRIIB specific antibodies and methods of use thereof |
| US8187593B2 (en) | 2002-08-14 | 2012-05-29 | Macrogenics, Inc. | FcγRIIB specific antibodies and methods of use thereof |
| US7384744B2 (en) | 2002-11-29 | 2008-06-10 | Boehringer Ingelheim Pharma Gmbh & Co., Kg | Expression vector, methods for the production of heterologous gene products and for the selection of recombinant cells producing high levels of such products |
| JP2006524039A (ja) | 2003-01-09 | 2006-10-26 | マクロジェニクス，インコーポレーテッド | 変異型Ｆｃ領域を含む抗体の同定および作製ならびにその利用法 |
| US7960512B2 (en) | 2003-01-09 | 2011-06-14 | Macrogenics, Inc. | Identification and engineering of antibodies with variant Fc regions and methods of using same |
| EA200700469A1 (ru) * | 2003-02-14 | 2008-10-30 | Байоджен Айдек Ма Инк. | Экспрессионная кассета и вектор для временной или постоянной экспрессии экзогенных молекул |
| US7521542B2 (en) | 2004-05-10 | 2009-04-21 | Macrogenics, Inc. | Humanized FcγRIIB-specific antibodies and methods of use thereof |
| US7632497B2 (en) | 2004-11-10 | 2009-12-15 | Macrogenics, Inc. | Engineering Fc Antibody regions to confer effector function |
| PL1919503T3 (pl) | 2005-08-10 | 2015-04-30 | Macrogenics Inc | Identyfikacja i inżynieria przeciwciał ze zmiennymi regionami FC oraz sposoby ich stosowania |
| US10155816B2 (en) * | 2005-11-28 | 2018-12-18 | Genmab A/S | Recombinant monovalent antibodies and methods for production thereof |
| EP1806365A1 (en) | 2006-01-05 | 2007-07-11 | Boehringer Ingelheim International GmbH | Antibody molecules specific for fibroblast activation protein and immunoconjugates containing them |
| ES2489646T3 (es) | 2006-05-26 | 2014-09-02 | Macrogenics, Inc. | Anticuerpos humanizados específicos a Fc gamma RIIB y sus métodos de uso |
| PT2029173T (pt) | 2006-06-26 | 2016-11-02 | Macrogenics Inc | Anticorpos específicos fc rib e seus métodos de uso |
| WO2008002933A2 (en) | 2006-06-26 | 2008-01-03 | Macrogenics, Inc. | Combination of fcgammariib antibodies and cd20-specific antibodies and methods of use thereof |
| US8652466B2 (en) | 2006-12-08 | 2014-02-18 | Macrogenics, Inc. | Methods for the treatment of disease using immunoglobulins having Fc regions with altered affinities for FcγRactivating and FcγRinhibiting |
| CA2675233A1 (en) | 2007-01-16 | 2008-07-24 | Abbott Laboratories | Methods for treating psoriasis |
| AU2008233173B2 (en) | 2007-03-29 | 2013-09-19 | Abbvie Inc. | Crystalline anti-human IL-12 antibodies |
| WO2009151717A2 (en) | 2008-04-02 | 2009-12-17 | Macrogenics, Inc. | Bcr-complex-specific antibodies and methods of using same |
| EA022990B1 (ru) * | 2007-08-20 | 2016-04-29 | Глаксо Груп Лимитед | Способ получения клеточной линии млекопитающего, продуцирующей терапевтический белок |
| ATE524740T1 (de) * | 2007-12-10 | 2011-09-15 | Hoffmann La Roche | Seprase als krebsmarker |
| CA2701970A1 (en) * | 2007-12-10 | 2009-06-18 | F. Hoffmann-La Roche Ag | Marker panel for colorectal cancer |
| EP2071337A1 (en) * | 2007-12-10 | 2009-06-17 | F.Hoffmann-La Roche Ag | Seprase as a marker for cancer |
| US8557239B2 (en) | 2009-09-14 | 2013-10-15 | Abbvie Inc. | Methods for treating psoriasis using antibodies that bind to the P40 subunit of IL-12 and/or IL-23 |
| TWI461210B (zh) | 2008-03-18 | 2014-11-21 | Abbvie Inc | 治療牛皮癬的方法 |
| PT2247304T (pt) | 2008-04-02 | 2016-08-29 | Macrogenics Inc | Anticorpos especificos de her2/neu e métodos de utilização dos mesmos |
| TR201804897T4 (tr) | 2009-10-07 | 2018-06-21 | Macrogenics Inc | Fukosi̇lasyon ölçüsünün deği̇şi̇mleri̇nden dolayi geli̇şmi̇ş efektör i̇şlevi̇ sergi̇leyen fc bölgesi̇ni̇ i̇çeren poli̇pepti̇tler ve bunlarin kullanimlarina yöneli̇k yöntemler |
| PH12012501751A1 (en) | 2010-03-04 | 2012-11-12 | Macrogenics Inc | Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof |
| SG10201604336VA (en) | 2010-03-04 | 2016-07-28 | Macrogenics Inc | Antibodies Reactive With B7-H3, Immunologically Active Fragments Thereof And Uses Thereof |
| HUE036077T2 (hu) * | 2010-08-13 | 2018-06-28 | Roche Glycart Ag | Anti-FAP ellenanyagok és alkalmazásukra szolgáló eljárások |
| CA2810359C (en) | 2010-09-09 | 2021-06-22 | Pfizer Inc. | 4-1bb binding molecules |
| CN105440123B (zh) | 2011-02-10 | 2020-10-09 | 罗切格利卡特公司 | 突变体白介素-2多肽 |
| ES2718478T3 (es) | 2012-06-08 | 2019-07-02 | Sutro Biopharma Inc | Anticuerpos que comprenden restos de aminoácidos no naturales de localización específica, métodos para su preparación y métodos para su uso |
| DK2863955T3 (en) | 2012-06-26 | 2017-01-23 | Sutro Biopharma Inc | MODIFIED FC PROTEINS, INCLUDING LOCATION-SPECIFIC NON-NATURAL AMINO ACID RESIDUES, CONJUGATES THEREOF, METHODS OF PRODUCING ITS AND PROCEDURES FOR USE THEREOF |
| US9487587B2 (en) | 2013-03-05 | 2016-11-08 | Macrogenics, Inc. | Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof |
| UA118028C2 (uk) | 2013-04-03 | 2018-11-12 | Рош Глікарт Аг | Біспецифічне антитіло, специфічне щодо fap і dr5, антитіло, специфічне щодо dr5, і спосіб їх застосування |
| CN103267852B (zh) * | 2013-05-15 | 2015-03-25 | 中国医学科学院北京协和医院 | 成纤维激活蛋白α在制备胰腺癌预后试剂盒中的用途 |
| ES2865473T3 (es) | 2013-07-10 | 2021-10-15 | Sutro Biopharma Inc | Anticuerpos que comprenden múltiples residuos de aminoácidos no naturales sitio-específicos, métodos para su preparación y métodos de uso |
| GB201402006D0 (en) | 2014-02-06 | 2014-03-26 | Oncomatryx Biopharma S L | Antibody-drug conjugates and immunotoxins |
| LT3653644T (lt) * | 2014-03-26 | 2024-01-25 | Julius-Maximilians-Universität Würzburg | Monokloniniai antikūnai prieš augimo ir diferenciacijos faktorių 15 (gdf- 15), ir jų panaudojimas taikant vėžio kacheksijos ir vėžio gydymą |
| CN105646710B (zh) * | 2014-11-17 | 2020-08-25 | 四川科伦博泰生物医药股份有限公司 | 一种全人源化抗vegfr-2单克隆抗体及其制备方法 |
| KR20180053674A (ko) | 2015-10-02 | 2018-05-23 | 에프. 호프만-라 로슈 아게 | 공자극 tnf 수용체에 특이적인 이중특이성 항체 |
| CA3011455A1 (en) * | 2016-01-27 | 2017-08-03 | Sutro Biopharma, Inc. | Anti-cd74 antibody conjugates, compositions comprising anti-cd74 antibody conjugates and methods of using anti-cd74 antibody conjugates |
| US10961311B2 (en) | 2016-04-15 | 2021-03-30 | Macrogenics, Inc. | B7-H3 binding molecules, antibody drug conjugates thereof and methods of use thereof |
| EP3478321A4 (en) | 2016-06-30 | 2020-04-22 | Oncorus, Inc. | Pseudotyped oncolytic viral delivery of therapeutic polypeptides |
| JP2018035137A (ja) | 2016-07-13 | 2018-03-08 | マブイミューン ダイアグノスティックス エイジーＭａｂｉｍｍｕｎｅ Ｄｉａｇｎｏｓｔｉｃｓ Ａｇ | 新規な抗線維芽細胞活性化タンパク質（ｆａｐ）結合薬剤およびその使用 |
| JP7162592B2 (ja) | 2016-12-14 | 2022-10-28 | パーデュー・リサーチ・ファウンデイション | 線維芽細胞活性化タンパク質（ｆａｐ）標的イメージングおよび治療 |
| JP2021508477A (ja) | 2017-12-29 | 2021-03-11 | オンコラス， インコーポレイテッド | 治療用ポリペプチドの腫瘍溶解性ウイルス送達 |
| CN110526991A (zh) * | 2018-05-25 | 2019-12-03 | 深圳宾德生物技术有限公司 | 靶向fap的嵌合抗原受体、嵌合抗原受体t细胞及其制备方法和应用 |
| CN110526979A (zh) * | 2018-05-25 | 2019-12-03 | 深圳宾德生物技术有限公司 | 靶向fap的单链抗体、嵌合抗原受体t细胞及其制备方法和应用 |
| CN109053893B (zh) * | 2018-08-15 | 2021-03-30 | 智享生物(苏州)有限公司 | 一种抗d-二聚体单克隆抗体及其制备方法 |
| CN112972675A (zh) * | 2018-09-07 | 2021-06-18 | 上海君实生物医药科技股份有限公司 | 抗pd-1抗体在治疗肿瘤中的用途 |
| CN114853908B (zh) * | 2019-05-16 | 2024-06-07 | 浙江道尔生物科技有限公司 | 一种治疗代谢疾病的融合蛋白 |
| EP3997104A1 (en) | 2019-07-08 | 2022-05-18 | 3B Pharmaceuticals GmbH | Compounds comprising a fibroblast activation protein ligand and use thereof |
| IL289675B1 (en) | 2019-07-08 | 2025-09-01 | 3B Pharmaceuticals Gmbh | Compounds comprising a protein ligand for fibroblast activation and their use |
| EP3763726A1 (en) | 2019-07-08 | 2021-01-13 | 3B Pharmaceuticals GmbH | Compounds comprising a fibroblast activation protein ligand and use thereof |
| US12371491B2 (en) | 2019-09-03 | 2025-07-29 | Bio-Thera Solutions, Ltd. | Anti-TIGIT immunosuppressant and application thereof |
| CN113512116B (zh) * | 2020-04-10 | 2022-09-20 | 苏州普乐康医药科技有限公司 | 一种抗igf-1r抗体及其应用 |
| KR102363980B1 (ko) * | 2020-04-13 | 2022-02-15 | 전남대학교산학협력단 | 전이성 뇌종양의 진단 또는 예후 분석용 바이오마커 및 이를 이용한 진단방법 |
| US20230174649A1 (en) * | 2020-04-30 | 2023-06-08 | I-Mab Biopharma Us Limited | Pharmaceutical compositions containing anti-cd47 antibodies |
| KR20230012559A (ko) | 2020-05-19 | 2023-01-26 | 베링거 인겔하임 인터내셔날 게엠베하 | 암 치료를 위한 결합 분자 |
| WO2022007283A1 (zh) * | 2020-07-08 | 2022-01-13 | 深圳霁因生物医药转化研究院 | 用于诊断fap表达异常相关疾病的试剂盒、方法及计算机可读存储介质 |
| KR102799318B1 (ko) * | 2020-08-11 | 2025-04-23 | 주식회사 카나프테라퓨틱스 | Il-12 및 항-fap 항체를 포함하는 융합단백질 및 이의 용도 |
| EP4050018A1 (en) | 2021-01-07 | 2022-08-31 | 3B Pharmaceuticals GmbH | Compounds comprising a fibroblast activation protein ligand and use thereof |
| AU2022205523A1 (en) | 2021-01-07 | 2023-07-13 | 3B Pharmaceuticals Gmbh | Compounds comprising a fibroblast activation protein ligand and use thereof |
| WO2023031644A1 (en) | 2021-08-31 | 2023-03-09 | Full-Life Technologies Limited | Anti-fibroblast activation protein (fap) single domain antibodies and uses thereof |
| JP2025503533A (ja) * | 2021-12-30 | 2025-02-04 | コンセプト トゥー メディシン バイオテック カンパニー， リミテッド | Ｆａｐ－アルファに対するヒト抗体 |
| CN119604540A (zh) * | 2022-08-03 | 2025-03-11 | 南京维立志博生物科技股份有限公司 | 靶向FAP和TGFβ的抗体融合蛋白及其用途 |
| CN120112308A (zh) | 2022-10-07 | 2025-06-06 | 吉尼松公司 | 使用抗fap car-t细胞免疫治疗骨骼肌病 |
| CN116589566A (zh) * | 2022-11-18 | 2023-08-15 | 昆明医科大学第一附属医院 | 一种HIV-1中和抗体的改造重组单克隆IgM抗体及其应用 |
| CN120309735A (zh) * | 2024-01-15 | 2025-07-15 | 迈威(上海)生物科技股份有限公司 | 重组抗fap抗体及其应用 |
| CN118496382B (zh) * | 2024-05-22 | 2025-01-07 | 山东第一医科大学附属省立医院(山东省立医院) | 一种靶向fap的嵌合抗原受体、car-t细胞及其在肝纤维化中的应用 |
| CN119265201A (zh) * | 2024-08-23 | 2025-01-07 | 中国人民解放军海军军医大学第一附属医院 | 编码基因、蛋白、表达il-15的nkg2dl-fap双靶点car-nk细胞及其构建方法和用途 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5059523A (en) * | 1988-05-02 | 1991-10-22 | Sloan-Kettering Institute For Cancer Research | Cell-surface glycoproteins of human sarcomas |
| US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| AU2782292A (en) * | 1991-09-18 | 1993-04-27 | Sloan-Kettering Institute For Cancer Research | Activated stromal fibroblast-specific antibody, f19 and methods of using the same |
| ZA936260B (en) * | 1992-09-09 | 1994-03-18 | Smithkline Beecham Corp | Novel antibodies for conferring passive immunity against infection by a pathogen in man |
| ES2176484T3 (es) * | 1995-08-18 | 2002-12-01 | Morphosys Ag | Bancos de proteinas/(poli)peptidos. |
| AU716257B2 (en) * | 1996-05-01 | 2000-02-24 | Genitope Corporation | Vaccines for treatment of lymphoma and leukemia |
-
1998
- 1998-04-30 EP EP98107925A patent/EP0953639A1/en not_active Withdrawn
-
1999
- 1999-04-22 KR KR1020007011585A patent/KR100580936B1/ko not_active Expired - Fee Related
- 1999-04-22 UA UA2000116786A patent/UA73276C2/uk unknown
- 1999-04-22 ES ES99923439T patent/ES2283114T3/es not_active Expired - Lifetime
- 1999-04-22 YU YU66300A patent/YU66300A/sh unknown
- 1999-04-22 CN CN99806582A patent/CN1303430A/zh active Pending
- 1999-04-22 WO PCT/EP1999/002711 patent/WO1999057151A2/en not_active Ceased
- 1999-04-22 DE DE69935516T patent/DE69935516T2/de not_active Expired - Lifetime
- 1999-04-22 ID IDW20002198A patent/ID26555A/id unknown
- 1999-04-22 HU HU0101501A patent/HUP0101501A3/hu unknown
- 1999-04-22 AU AU40322/99A patent/AU760305B2/en not_active Ceased
- 1999-04-22 JP JP2000547119A patent/JP4421779B2/ja not_active Expired - Lifetime
- 1999-04-22 EE EEP200000642A patent/EE200000642A/xx unknown
- 1999-04-22 TR TR2000/03181T patent/TR200003181T2/xx unknown
- 1999-04-22 AT AT99923439T patent/ATE356873T1/de active
- 1999-04-22 EP EP99923439A patent/EP1098979B1/en not_active Expired - Lifetime
- 1999-04-22 CA CA2327586A patent/CA2327586C/en not_active Expired - Lifetime
- 1999-04-22 NZ NZ508456A patent/NZ508456A/xx unknown
- 1999-04-22 PL PL99358087A patent/PL358087A1/xx not_active IP Right Cessation
- 1999-04-22 BR BR9910577-2A patent/BR9910577A/pt not_active IP Right Cessation
- 1999-04-22 EA EA200001023A patent/EA005401B1/ru not_active IP Right Cessation
- 1999-04-22 SK SK1619-2000A patent/SK16192000A3/sk unknown
- 1999-04-22 IL IL13870199A patent/IL138701A0/xx unknown
- 1999-04-29 CO CO99025997A patent/CO5050255A1/es unknown
- 1999-04-30 AR ARP990102015A patent/AR016243A1/es unknown
-
2000
- 2000-10-05 BG BG104828A patent/BG65034B1/bg unknown
- 2000-10-09 ZA ZA200005506A patent/ZA200005506B/en unknown
- 2000-10-27 NO NO20005412A patent/NO20005412L/no not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR016243A1 (es) | Un anticuerpo proteico que tiene las regiones determinantes de la complementariedad del anticuerpo monoclonal f19 y que se fija especificamente a laproteina de activacion de fibroblastos; el empleo de dicho anticuerpo proteico para el tratamiento del cancer, para representar en imagenes fibroblastos | |
| Zhu et al. | A microdevice for multiplexed detection of T-cell-secreted cytokines | |
| EP0914155A4 (en) | PROSTATE SPECIFIC MEMBRANE ANTIGEN MONOCLONAL ANTIBODIES | |
| AR045056A1 (es) | Anticuerpos anti-ngf humanos neutralizantes como inhibidores selectivos de la via de ngf | |
| RU2010148904A (ru) | Антитела к интерлейкину-1альфа и способы применения | |
| AR038700A1 (es) | Anticuerpos monoclonales anti-tenascina humana | |
| PT1190257E (pt) | Deteccao precoce dos flavivirus, utilizando a glicoproteina ns1 | |
| ATE410680T1 (de) | Sekretion von proteinen durch verkapselte zellen | |
| EA199700447A1 (ru) | Последовательность днк и кодируемый ею специфический для молочной железы белок карциномы молочной железы | |
| DE50115587D1 (de) | Verfahren zur Herstellung von Protein-Bibliotheken und zur Selektion von Proteinen daraus | |
| JP2002521391A5 (enExample) | ||
| EP1734366A3 (de) | Neues Verfahren zum Nachweis von Säure-resistenten Mikroorganismen im Stuhl | |
| PE20232050A1 (es) | Anticuerpos anti-cd19 y estructuras car-t | |
| González-González et al. | Evaluation of homo-and hetero-functionally activated glass surfaces for optimized antibody arrays | |
| IE810795L (en) | Monoclonal antibodies against hepatitis b virus | |
| JP4503293B2 (ja) | 機能化材料およびそのライブラリー | |
| WO2002094853A3 (en) | Antibodies specific for poly(ethylene glycol) | |
| AR123537A1 (es) | Anticuerpo contra hla-dq2.5 y su uso para el tratamiento de la enfermedad celíaca | |
| RU94046414A (ru) | Моноклональные антитела к гликопротеину р, их получение и применение, продуцирующие их клетки, иммунологический диагностический набор на их основе, терапевтический состав | |
| KR890702031A (ko) | 사람의 감마, 델타 t세포 항원수용체 폴리펩티드 및 헥산 | |
| Rubin et al. | Hepatocyte adhesion to collagen: isolation of membrane glycoproteins involved in adhesion to collagen | |
| FI3857237T3 (fi) | Disulfidisidosten luonnehtimismenetelmiä | |
| Hořejší et al. | Nitrocellulose membrane as an antigen or antibody carrier for screening hybridoma cultures | |
| CA2349217A1 (en) | Cancer-associated antigens and methods of their identification | |
| AU2003283240A1 (en) | Antibody for isolating and/or identifying mesenchymal stem cells and method for isolating and/or identifying mesenchymal stem cells |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |